Ultra-low-molecular-weight heparins: Precise structural features impacting specific anticoagulant activities

Thrombosis and Haemostasis

Volumn 109, Issue 3, 2013, Pages 471-478

  Lima, Marcelo A ^a,b   Viskov, Christian ^c   Herman, Frederic ^c   Gray, Angel L ^d   de Farias, Eduardo H C ^a   Cavalheiro, Renan P ^a   Sassaki, Guilherme L ^e   Hoppensteadt, Debra ^d   Fareed, Jawed ^d   Nader, Helena B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Institute of Integrative Biology   (United Kingdom)

^c Vitry sur Seine ^*  (United Kingdom)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^e FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Anticoagulant activity; Enoxaparin; Heparin; Molecular weight; Spectroscopy

Indexed keywords

BEMIPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; MONOSACCHARIDE; OLIGOSACCHARIDE; SEMULOPARIN; URONIC ACID;

ANTICOAGULATION; ARTICLE; CHROMATOPHORE; CIRCULAR DICHROISM; COMPARATIVE STUDY; FLOW RATE; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROPHYLAXIS; PROTON NUCLEAR MAGNETIC RESONANCE; ULTRAVIOLET SPECTROSCOPY;

ANTICOAGULANTS; CARBOHYDRATE SEQUENCE; CIRCULAR DICHROISM; ENOXAPARIN; GLUCOSAMINE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; OLIGOSACCHARIDES; POLYMERS; SPECTROPHOTOMETRY, ULTRAVIOLET; THROMBOSIS; URONIC ACIDS;

EID: 84874789691     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-11-0795     Document Type: Article

References (21)

1. Nader HB, McDuffie NM, Dietrich CP. Heparin fractionation by electrofocusing: presence of 21 components of different molecular weights. Biochem Biophys Res Commun 1974; 57: 488-493.
2. McDuffie NM, Dietrich CP, Nader HB. Electrofocusing of heparin: fractionation of heparin into 21 components distinguishable from other acidic mucopolysaccharides. Biopolymers 1975; 14: 1473-1486.
3. Dietrich CP, Nader HB, Perlin AS. The heterogeneity of heparan sulfate from beef-lung tissue: p.m.r.-spectral evidence. Carbohydr Res 1975; 41: 334-338.
4. Bianchini P, Osima B, Parma B, et al. Structural studies and "in vivo" and "in vitro" pharmacological activities of heparin fractions and fragments prepared by chemical and enzymic depolimerization. Thromb Res 1985; 40: 49-58.
5. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 454S-545S.
6. Jin L, Abrahams JP, Skinner R, et al. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-14688.
7. Viskov C, Just M, Laux V, et al. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost 2009; 7: 1143-1151.
8. Guerrini M, Guglieri S, Naggi A, et al. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost 2007; 33: 478-487.
9. Vismara E, Pierini M, Mascellani G, et al. Low-molecular-weight heparin from Cu2+ and Fe2+ Fenton type depolymerisation processes. Thromb Haemost 2010; 103: 613-622.
10. Ahsan A, Jeske W, Hoppensteadt D, et al. Molecular profiling and weight determination of heparins and depolymerized heparins. J Pharm Sci 1995; 84: 724-727.
11. Clevidence BA, Failla ML, Vercellotti JR, et al. Pharmacokinetics of catalytically tritiated glycosaminoglycans in the rat. Arzneimittelforschung 1983; 33: 228-230.
12. Viccini G, Martinelli TR, Cognialli RC, et al. Exopolysaccharide from surfaceliquid culture of Clonostachys rosea originates from autolysis of the biomass. Arch Microbiol 2009; 191: 369-378.
13. Bednarek E, Sitkowski J, Bocian W, et al. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method. J Pharm Biomed Anal 2010; 53: 302-308.
14. Biberovic V, Grondard L, Mourier P, et al., inventors; Aventis Pharma S.A., assignee. Mixtures of sulfated oligosaccharides. USA. 2011.
15. Guerrini M, Naggi A, Guglieri S, et al. Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem 2005; 337: 35-47.
16. Lima MA, de Farias EHC, Rudd TR, et al. Low molecular weight heparins: Structural differentiation by spectroscopic and multivariate approaches. Carbohyd Polym 2011; 85: 903-909.
17. Mascellani G, Guerrini M, Torri G, et al. Characterization of di-and monosulfated, unsaturated heparin disaccharides with terminal N-sulfated 1,6-anhydrobeta-D-glucosamine or N-sulfated 1,6-anhydro-beta-D-mannosamine residues. Carbohydr Res 2007; 342: 835-842.
18. Enoxaparin Sodium Monograph. Pharmacopeial Forum 2009; 35: 2041-2042.
19. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (5 Suppl): 489S-510S.
20. Guerrini M, Guglieri S, Casu B, et al. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue. J Biol Chem 2008; 283: 26662-26675.
21. Martinez-Gonzalez J, Vila L, Rodriguez C. Bemiparin: second-generation, lowmolecular-weight heparin for treatment and prophylaxis of venous thromboembolism. Expert Rev Cardiovasc Ther 2008; 6: 793-802.